The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice
Open accessAbstract
MicroRNAs inhibit mRNA translation or promote mRNA degradation by binding complementary sequences in 3' untranslated regions of target mRNAs. MicroRNA-21 (miR-21) is upregulated in response to cardiac stress, and its inhibition by a cholesterol-modified antagomir has been reported to prevent cardiac hypertrophy and fibrosis in rodents in response to pressure overload. In contrast, we have shown here that miR-21-null mice are normal and, in response to a variety of cardiac stresses, display cardiac hypertrophy, fibrosis, upregulation of stress-responsive cardiac genes, and loss of cardiac contractility comparable to wild-type littermates. Similarly, inhibition of miR-21 through intravenous delivery of a locked nucleic acid-modified (LNA-modified) antimiR oligonucleotide also failed to block the remodeling response of the heart to stress. We therefore conclude that miR-21 is not essential for pathological cardiac remodeling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Self-citationMicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Self-citationControl of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Self-citationLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 1×
“Therapeutic efficacy of LNAantimiR technology has recently been reported (21, 22).”
BackgroundSelf-citationvan Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., Richardson, J. A., & Olson, E. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608791103 · Cited by 1,507
Self-citationTherapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Self-citationHill, J. A., & Olson, E. N. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072139 · Cited by 1,065
Self-citationmiR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure
Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., Doevendans, P. A., Mummery, C. L., Borlak, J., Haverich, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.687947 · Cited by 888
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“Nevertheless, a recent study with miR-21–null mice has raised questions about the overall importance of miR-21 in pathological cardiac remodeling 141 .”
MicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
Self-citationPervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180
Self-citationCardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
Self-citationRegulation and function of miRNA-21 in health and disease
Kumarswamy, R., Volkmann, I., & Thum, T. (2011) · RNA Biology · doi:10.4161/rna.8.5.16154 · Cited by 607
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Self-citationRecent advances in the molecular pathophysiology of atrial fibrillation
Wakili, R., Voigt, N., Kääb, S., Dobrev, D., & Nattel, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46315 · Cited by 545
Ma, X., Becker Buscaglia, L. E., Barker, J. R., & Li, Y. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr007 · Cited by 542
Inhibition of miR-15 Protects Against Cardiac Ischemic Injury
Hullinger, T. G., Montgomery, R. L., Seto, A. G., Dickinson, B. A., Semus, H. M., Lynch, J. M., Dalby, C. M., Robinson, K., Stack, C., Latimer, P. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.244442 · Cited by 501
Self-citationTurning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response
Sheedy, F. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00019 · Cited by 496
The biological functions of miRNAs: lessons from in vivo studies
Vidigal, J. A., & Ventura, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.004 · Cited by 488
Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., Renard, J.-M., Mayr, A., Weger, S., Schett, G., Shah, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.056 · Cited by 464
Developing MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
Self-citationMicroRNAs in Cardiovascular Disease
Barwari, T., Joshi, A., & Mayr, M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.945 · Cited by 445
Aurora, A. B., Mahmoud, A. I., Luo, X., Johnson, B. A., van Rooij, E., Matsuzaki, S., Humphries, K. M., Hill, J. A., Bassel-Duby, R., Sadek, H. A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59327 · Cited by 404
Self-citationLong Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology
Thum, T., & Condorelli, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.303549 · Cited by 385
Apoptosis and the target genes of microRNA-21
Buscaglia, L. E. B., & Li, Y. (2011) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10132 · Cited by 378
microRNAs in Cardiovascular Diseases
Condorelli, G., Latronico, M. V. G., & Cavarretta, E. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.050 · Cited by 375
Lu, T. X., Hartner, J., Lim, E.-J., Fabry, V., Mingler, M. K., Cole, E. T., Orkin, S. H., Aronow, B. J., & Rothenberg, M. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101235 · Cited by 341
Adult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Hinkel, R., Penzkofer, D., Zühlke, S., Fischer, A., Husada, W., Xu, Q.-F., Baloch, E., van Rooij, E., Zeiher, A. M., Kupatt, C., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001904 · Cited by 317
Self-citationQiao, L., Hu, S., Liu, S., Zhang, H., Ma, H., Huang, K., Li, Z., Su, T., Vandergriff, A., Tang, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123135 · Cited by 303
The fibrosis-cell death axis in heart failure
Piek, A., de Boer, R. A., & Silljé, H. H. W. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9536-9 · Cited by 301
MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment
Quiat, D., & Olson, E. N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62876 · Cited by 300
Self-citationParikh, V. N., Jin, R. C., Rabello, S., Gulbahce, N., White, K., Hale, A., Cottrill, K. A., Shaik, R. S., Waxman, A. B., Zhang, Y.-Y., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.060269 · Cited by 265
Henao-Mejia, J., Williams, A., Goff, L. A., Staron, M., Licona-Limón, P., Kaech, S. M., Nakayama, M., Rinn, J. L., & Flavell, R. A. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.021 · Cited by 263
MicroRNAs as Therapeutic Targets and Biomarkers of Cardiovascular Disease
Olson, E. N. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009008 · Cited by 255
Self-citationMicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, X. Y., Sinner, M. F., Dobrev, D., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001207 · Cited by 252
Self-citationMicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice
Horie, T., Nishino, T., Baba, O., Kuwabara, Y., Nakao, T., Nishiga, M., Usami, S., Izuhara, M., Sowa, N., Yahagi, N., et al. (2013) · Nature Communications · doi:10.1038/ncomms3883 · Cited by 230
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
MicroRNA therapeutics in cardiovascular medicine
Thum, T. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100191 · Cited by 193
Induction of Specific MicroRNAs Inhibits Cutaneous Wound Healing
Pastar, I., Khan, A. A., Stojadinovic, O., Lebrun, E. A., Medina, M. C., Brem, H., Kirsner, R. S., Jimenez, J. J., Leslie, C., & Tomic-Canic, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382135 · Cited by 132
“However, contradictory results obtained from studies using different approaches to inhibit miR-21 in other tissues such as cardiac suggest that caution is neededwhen interpreting results using antisense oligonucleotides or antagomirs (63).”
ResultChuppa, S., Liang, M., Liu, P., Liu, Y., Casati, M. C., Cowley, A. W., Patullo, L., & Kriegel, A. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.05.014 · Cited by 99
Metadata
- Authors
- Patrick, D. M., Montgomery, R. L., Qi, X., Obad, S., Kauppinen, S., Hill, J. A., van Rooij, E., & Olson, E. N.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-11-01
- Volume
- 120
- Issue
- 11
- Pages
- 3912-3916
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2150037286
- Cited by
- 360
- References
- 23
- FWCI
- 31.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.